Prometic Life Sciences Inc.

PLI-T

TSE:PLI

13.60
0.03 (0.22%)
Prometic Life Sciences Inc. is a Canadian publicly traded biopharmaceutical company. Prometic products are used in the purification of biologics, drug development, proteomics and the removal of pathogens.
More at Wikipedia

Analysis and Opinions about PLI-T

Signal
Opinion
Expert
COMMENT
COMMENT
November 11, 2014

Biotechnology sector is one that he does embrace. As a group it is going higher. This one has clearly broken out and has hit a new 52-week high today. This does go higher. As a group, they are risky. He would recommend buying a basket rather than an individual stock.

Show full opinionHide full opinion

Biotechnology sector is one that he does embrace. As a group it is going higher. This one has clearly broken out and has hit a new 52-week high today. This does go higher. As a group, they are risky. He would recommend buying a basket rather than an individual stock.

TOP PICK
TOP PICK
November 10, 2014

Manufacturing company with a bonus of having a drug called PBI4050, which supposedly works better than Intermune, and works even better in combination with the Intermune product. Have proprietary filtering technologies used for large-scale purification of drugs. They use their technology to extract plasma from blood. There are 3 proteins that they are extracting from the plasma including plasminogen, IBIG and AANT. Market cap of just under $1 billion.

Show full opinionHide full opinion

Manufacturing company with a bonus of having a drug called PBI4050, which supposedly works better than Intermune, and works even better in combination with the Intermune product. Have proprietary filtering technologies used for large-scale purification of drugs. They use their technology to extract plasma from blood. There are 3 proteins that they are extracting from the plasma including plasminogen, IBIG and AANT. Market cap of just under $1 billion.

COMMENT
COMMENT
October 22, 2014

He originally bought this for their plasma business where they take plasma out of blood and sell it. This is a huge business that could grow over time. This company is sort of a lottery ticket. They are working some of their drugs through different stages of trials right now. If they can get one of those, it would be a game changer. Their plasma business will be a significantly growing business over the years and provides cash flow for the company.

Show full opinionHide full opinion

He originally bought this for their plasma business where they take plasma out of blood and sell it. This is a huge business that could grow over time. This company is sort of a lottery ticket. They are working some of their drugs through different stages of trials right now. If they can get one of those, it would be a game changer. Their plasma business will be a significantly growing business over the years and provides cash flow for the company.

WATCH
WATCH
September 24, 2014

Tends to be very volatile in the short term. It runs way up, consolidates, and then pulls back a bit and then runs back up again. Have a lot in the pipeline of orphan drugs. Their main business is manufacturing a plasma that comes from blood, which is used in a lot of different pharmaceuticals’ products. As some of those pharmaceuticals get approved and through the FDA channels, the volume of plasma they sell is going to go up. Their “lottery ticket” side of the business are orphan drugs that are going through different phases right now through the approval stage. If you don’t own, watch for a bit of a pull back, which always tends to happen. When you get in, hold for a 3 or 5 year timeframe and you will do really well.

Show full opinionHide full opinion

Tends to be very volatile in the short term. It runs way up, consolidates, and then pulls back a bit and then runs back up again. Have a lot in the pipeline of orphan drugs. Their main business is manufacturing a plasma that comes from blood, which is used in a lot of different pharmaceuticals’ products. As some of those pharmaceuticals get approved and through the FDA channels, the volume of plasma they sell is going to go up. Their “lottery ticket” side of the business are orphan drugs that are going through different phases right now through the approval stage. If you don’t own, watch for a bit of a pull back, which always tends to happen. When you get in, hold for a 3 or 5 year timeframe and you will do really well.

TOP PICK
TOP PICK
August 29, 2014

Have an interesting drug PBI450. They basically do proprietary filtering. Could climb 80% in the next 12 months.

Show full opinionHide full opinion

Have an interesting drug PBI450. They basically do proprietary filtering. Could climb 80% in the next 12 months.

STRONG BUY
STRONG BUY
August 27, 2014

Thinks there is a lot of growth ahead for this company. Their basic business is basically separating proteins and plasmas out of the blood. Looking back at the history, this company probably should have been bankrupt, but it was kept alive because their technology is so good and is embedded in a lot of companies that are in trials right now to have their drugs approved. The upside lottery ticket is that they also have some orphan drugs that they are going to be going into clinical trials for themselves. If one of those was successful, it could do fantastic things to the stock.

Show full opinionHide full opinion

Thinks there is a lot of growth ahead for this company. Their basic business is basically separating proteins and plasmas out of the blood. Looking back at the history, this company probably should have been bankrupt, but it was kept alive because their technology is so good and is embedded in a lot of companies that are in trials right now to have their drugs approved. The upside lottery ticket is that they also have some orphan drugs that they are going to be going into clinical trials for themselves. If one of those was successful, it could do fantastic things to the stock.

DON'T BUY
DON'T BUY
April 22, 2014

Biotech tends to do well in the summertime from August through until October. There is another push at the end of the year from about October into February. Seasonality for this in particular is a bit different from the biotech sector. It actually enters a period of seasonal weakness during the summer. Seasonal strength is really from the end of December through to February. Wouldn’t be pursuing this, particularly seeing how stretched it has become.

Show full opinionHide full opinion

Biotech tends to do well in the summertime from August through until October. There is another push at the end of the year from about October into February. Seasonality for this in particular is a bit different from the biotech sector. It actually enters a period of seasonal weakness during the summer. Seasonal strength is really from the end of December through to February. Wouldn’t be pursuing this, particularly seeing how stretched it has become.

BUY
BUY
February 4, 2014

(Market Call Minute.) Very interesting company. Their filtration technology is getting a lot of attention. Have 2 orphan drugs proceeding along the way. Gaining cash from their partners and looks pretty good right now.

Show full opinionHide full opinion

(Market Call Minute.) Very interesting company. Their filtration technology is getting a lot of attention. Have 2 orphan drugs proceeding along the way. Gaining cash from their partners and looks pretty good right now.

BUY
BUY
January 31, 2014

Up 30% year to date. Believes there is still a lot of upside left. Feels there is good opportunity for them, particularly in the 2nd half of 2014 when you should see a lot of things start to happen and particularly 2015 when you actually see production potentially occurring in China.

Show full opinionHide full opinion

Up 30% year to date. Believes there is still a lot of upside left. Feels there is good opportunity for them, particularly in the 2nd half of 2014 when you should see a lot of things start to happen and particularly 2015 when you actually see production potentially occurring in China.

COMMENT
COMMENT
October 25, 2013

Likes the momentum it has. Technology is quite interesting with great potential on some of their products. Early results are very good but if anything goes wrong, a lot of expectations built into the stock will be disappointed. An investor will have to have patience and a tolerance for risk and you’ll have to not look at it for 1 or 2 years.

Show full opinionHide full opinion

Likes the momentum it has. Technology is quite interesting with great potential on some of their products. Early results are very good but if anything goes wrong, a lot of expectations built into the stock will be disappointed. An investor will have to have patience and a tolerance for risk and you’ll have to not look at it for 1 or 2 years.

BUY
BUY
October 9, 2013

The largest holding in his personal account. Make beads that basically can extract bad things of blood as well as extracting proteins out of plasma. Have announced a couple of orphan drugs that they will be targeting. Still lots more opportunity, particularly in 2014-2015.

Show full opinionHide full opinion

The largest holding in his personal account. Make beads that basically can extract bad things of blood as well as extracting proteins out of plasma. Have announced a couple of orphan drugs that they will be targeting. Still lots more opportunity, particularly in 2014-2015.

COMMENT
COMMENT
August 2, 2013

Have filters to extract extremely high proteins and components from plasma. Have a new drug PB1450 that is going into clinical trials in September and seems to do a really good job with exotic diseases. Expected to have decent earnings again in 2014.

Show full opinionHide full opinion

Have filters to extract extremely high proteins and components from plasma. Have a new drug PB1450 that is going into clinical trials in September and seems to do a really good job with exotic diseases. Expected to have decent earnings again in 2014.

TOP PICK
TOP PICK
February 1, 2013

Spent $460 million on technology that removes pathogens from blood. Recently got some money from a Chinese company that allows them to build out their Laval plant which will allow them to do 150,000 L a year, about $150 million capacity. P/E ratio of 35. Cheap.

Show full opinionHide full opinion

Spent $460 million on technology that removes pathogens from blood. Recently got some money from a Chinese company that allows them to build out their Laval plant which will allow them to do 150,000 L a year, about $150 million capacity. P/E ratio of 35. Cheap.

COMMENT
COMMENT
July 15, 2008
Very risky. Working on projects where the potential is substantial. Doesn’t always happen as the market hopes for.
Show full opinionHide full opinion
Very risky. Working on projects where the potential is substantial. Doesn’t always happen as the market hopes for.
BUY
BUY
June 18, 2008
Have a red blood cell booster for people who are going into chemotherapy. Have signed a couple of deals but he is really waiting for a joint venture. A “show me” stock. Good risk/reward.
Show full opinionHide full opinion
Have a red blood cell booster for people who are going into chemotherapy. Have signed a couple of deals but he is really waiting for a joint venture. A “show me” stock. Good risk/reward.
Showing 61 to 75 of 77 entries